Skip to main content Skip to megamenu (after main content)
Meet us next:   AACR Annual Meeting 2025 – 27-30 April  ●  ISCT Conference 2025 – 7-9 May  ●  more on our events calendar

Corporate News

Page (9)

Alvetex® named in the top ten life science innovations of 2010 by The Scientist magazine

06 December 2010

Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is proud to announce that Alvetex®, its breakthrough 3D cell culture technology, is among the winners of The Scientist magazine’s“Top 10 Life Science Innovations of 2010”.

Reinnervate launches Alvetex®, a breakthrough product for enabling routine 3D cell culture

22 November 2010

Reinnervate, is very pleased to announce today the first commercial launch of Alvetex®, its breakthrough 3D cell culture technology. find out more.

Reinnervate completes expansion into new purpose-built facility at NETPark

17 November 2010

Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced its expansion into a new purpose-built research and production facility at NETPark near Sedgefield, UK.

Reinnervate’s ec23® shown to enhance neuronal differentiation of human fetal neuroprogenitors and human embryonic stem cells

28 September 2010

Read more about Reinnervate’s ec23 and its ability to enhance neuronal differentiation as demonstrated in a paper published in Neuroscience Methods.

Reinnervate wins Chemistry Innovation / EPSRC Industrial CASE Award to fund development of Alvetex® for the 3D culture of liver cells

28 September 2010

Reinnervate has been granted a Chemistry Innovation Knowledge Transfer Network / EPSRC Industrial CASE Award to fund the development of a next-generation Alvetex® scaffold optimised for 3D hepatocyte culture.

Reinnervate has been accepted as a new member of the In Vitro Testing Industrial Platform (IVTIP)

14 September 2010

Reinnervate has been accepted into the In Vitro Testing Industrial Platform, advising European bodies on research projects in in vitro testing.

Reinnervate secures £1.8 million of investment to support commercialisation of Alvetex

27 May 2010

Reinnervate has successfully raised £1.8 million in new equity funding to complete the development of its Alvetex® 3D cell culture platform.